Five Prime Therapeutics to Host Research & Development Day on December 8, 2016
November 30 2016 - 4:05PM
Five Prime Therapeutics, Inc. (Nasdaq:FPRX), a clinical-stage
biotechnology company focused on discovering and developing
innovative immuno-oncology protein therapeutics, today announced it
will hold its Research & Development Day event for the
institutional investment community in New York City on Dec. 8,
2016. The formal program and webcast will begin at 8:00 a.m. ET and
will conclude at approximately 11:00 a.m. ET.
Five Prime will give in-depth presentations covering:
- An introduction of therapeutic candidates in IND-enabling
activities, including:
- a tetravalent GITR agonist antibody
- a T cell modulator
- and an additional multi-functional immune modulator
- An in-depth overview of the company’s unique preclinical
immuno-oncology discovery platform and screening progress
- A status update on clinical development programs
Planned presenters include senior executives from Five Prime's
scientific, clinical and management team as well as featured guest
speakers:
- Drew M. Pardoll, M.D., Ph.D., Abeloff
Professor of Oncology, Johns Hopkins University, School of
Medicine, Director, Bloomberg~Kimmel Institute for Cancer
Immunotherapy, Director, Cancer Immunology Program at the Sidney
Kimmel Comprehensive Cancer Center, Johns Hopkins
University
- Daniel Catenacci, M.D., Assistant Professor,
University of Chicago, Associate Director, Gastrointestinal
Oncology Program
- Robert Albert Anders, M.D., Ph.D., Associate
Professor of Pathology, Johns Hopkins University School of
Medicine
- Nils Lonberg, Ph.D., Senior Vice President,
Biologics Discovery, Bristol-Myers Squibb
The live webcast will be accessible at
http://investor.fiveprime.com/events.cfm or directly at
http://edge.media-server.com/m/p/j23gtgih. Five Prime will
maintain an archived replay of the webcast on its website for 30
days after the conference. For additional information, please email
amy.kendall@fiveprime.com.
About Five PrimeFive Prime Therapeutics, Inc.
discovers and develops innovative therapeutics to improve the lives
of patients with serious diseases. Five Prime's comprehensive
discovery platform, which encompasses virtually every medically
relevant extracellular protein, positions it to explore pathways in
cancer, inflammation and their intersection in immuno-oncology, an
area with significant therapeutic potential and a growing focus of
the company's R&D activities. Five Prime has entered into
strategic collaborations with leading global pharmaceutical
companies and has promising product candidates in clinical and late
preclinical development. For more information, please visit
www.fiveprime.com.
Cautionary Note on Forward-looking
StatementsThis press release contains forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995. Words such as "may," "will," "expect," "plan,"
"anticipate," "estimate," "intend" and similar expressions (as well
as other words or expressions referencing future events, conditions
or circumstances) are intended to identify forward-looking
statements. These forward-looking statements are based on Five
Prime's expectations and assumptions as of the date of this press
release. Each of these forward-looking statements involves risks
and uncertainties. Actual results may differ materially from these
forward-looking statements. Forward-looking statements contained in
this press release include statements regarding Five Prime's
potential receipt of upfront and milestone payments and royalties.
Factors that may cause actual results to differ from those
expressed or implied in the forward-looking statements in this
press release are discussed in Five Prime's filings with the U.S.
Securities and Exchange Commission, including the "Risk Factors"
contained therein. Except as required by law, Five Prime assumes no
obligation to update any forward-looking statements contained
herein to reflect any change in expectations, even as new
information becomes available.
CONTACTS:
Heather Rowe
Investor Relations
415-365-5737
heather.rowe@fiveprime.com
Amy Kendall
Corporate Communications
415-365-5776
amy.kendall@fiveprime.com
Five Prime Therapeutics (NASDAQ:FPRX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Five Prime Therapeutics (NASDAQ:FPRX)
Historical Stock Chart
From Apr 2023 to Apr 2024